TY - JOUR
T1 - Study of the profile of the neurotrophin BDNF in new leprosy cases before, during and after multidrug therapy
AU - Costa, Rosane Dias
AU - Mendonça, Vanessa Amaral
AU - Penido, Rachel Adriana
AU - Lyon, Sandra
AU - Dias Costa, Ana Maria Duarte
AU - Costa, Marina Dias
AU - de Souza Terra, Fábio
AU - Bretas, Thales Lage
AU - de Figueiredo Antunes, Carlos Maurício
AU - Teixeira, Antônio Lúcio
PY - 2011
Y1 - 2011
N2 - Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2nd dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment.
AB - Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2nd dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment.
KW - BDNF
KW - Biomarker
KW - Follow-up
KW - Leprosy
KW - Peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=79952339601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952339601&partnerID=8YFLogxK
U2 - 10.1590/S0004-282X2011000100019
DO - 10.1590/S0004-282X2011000100019
M3 - Article
C2 - 21359431
AN - SCOPUS:79952339601
SN - 0004-282X
VL - 69
SP - 100
EP - 104
JO - Arquivos de neuro-psiquiatria
JF - Arquivos de neuro-psiquiatria
IS - 1
ER -